UnitedHealth Group, one of America’s largest health insurers, is at the center of a storm that has left investors, policy watchers, and millions of patients on edge. Over the past year, the company’s stock price has tumbled, regulatory scrutiny has intensified, and leadership has been rocked by controversy and tragedy. With new developments arriving almost daily—from federal investigations to looming Medicare payment changes—stakeholders are scrambling to make sense of what’s next for the healthcare giant and the broader industry it so heavily influences.
On February 23, 2026, UnitedHealth Group’s stock closed at $290, capping a year marked by sharp declines: a 1.1% drop in the past week, 18.6% over the past month, and a staggering 36.3% slide over the last year. According to Simply Wall St, this downturn has prompted many to question whether the company’s share price truly reflects its underlying value. Their discounted cash flow (DCF) analysis pegs UnitedHealth’s intrinsic value at $818.37 per share—suggesting the stock may be undervalued by as much as 64.6%. By their metrics, the insurer is trading far below its modeled worth, an assessment echoed by other valuation methods. For instance, UnitedHealth’s price-to-earnings (P/E) ratio stands at 21.8x, just above its peer average but below the broader healthcare industry’s 23.9x. Yet, a tailored “Fair Ratio” P/E of 40.2x points to more room for growth, at least on paper.
But numbers only tell part of the story. The company is facing real-world headwinds that go beyond market models. On February 20, UnitedHealth shares finished flat at $290, then dipped slightly after hours to $289.19, as reported by StockAnalysis. The day’s trading volume reached nearly 6.9 million shares, with a range from $285.55 to $290.80. These modest movements masked deeper anxieties about the future, especially as the Centers for Medicare & Medicaid Services (CMS) opened a crucial comment period on its 2027 Medicare Advantage and Part D proposals. The final decision on payment rates, expected by April 6, could have massive implications for UnitedHealth and its rivals.
CMS’s draft plan would increase average Medicare Advantage payments by a mere 0.09% in 2027, while also tightening risk adjustment rules—meaning insurers could receive less money for certain diagnoses unless stricter criteria are met. As CMS Administrator Dr. Mehmet Oz put it, the goal is “making sure Medicare Advantage works better for the people it serves.” The agency is accepting feedback until February 25, a deadline that has become a focal point for investors and industry insiders alike. According to MarketWatch, UnitedHealth managed to hold up better than competitors like Cigna, Elevance, CVS, and Humana, all of which saw their stocks slip on February 20.
Yet, UnitedHealth’s challenges extend beyond regulatory tweaks. The company is under active investigation by the U.S. Department of Justice for its Medicare billing practices. The probe, which began in the summer of 2024, centers on allegations that UnitedHealth and other insurers used extra or incorrect diagnoses—sometimes not made by the treating doctors—to secure additional federal payments through the Medicare Advantage program. The Wall Street Journal first brought these issues to light in December 2024, raising uncomfortable questions about industry-wide billing techniques. In response, UnitedHealth said, “The Company has full confidence in its practices and is committed to working cooperatively with the Department throughout this process.” The insurer also launched its own third-party review of risk assessment coding, managed care practices, and pharmacy services in an effort to demonstrate transparency and compliance.
But the fallout has been severe. Over the past year, UnitedHealth’s stock has fallen by roughly 50%, a decline fueled by not just regulatory scrutiny but also a series of leadership crises and financial disappointments. In May 2024, the company and several senior executives—including founder and group chairman Stephen Hemsley and then-UnitedHealthcare CEO Brian Thompson—were sued for insider trading. The lawsuit, brought by a Hollywood-based pension fund, alleged that executives sold more than $100 million in stock after learning of the Department of Justice’s antitrust probe but before the news became public. The saga took a tragic turn in December when Brian Thompson was shot and killed in Manhattan on the morning of the company’s annual investor meeting—a shocking event that sent ripples through the industry and stoked public anger over UnitedHealthcare’s handling of claims and denials.
Financially, the company has struggled to reassure investors. Its earnings reports have repeatedly missed analyst expectations, and UnitedHealth’s medical care ratio—a key metric showing the proportion of premiums spent on patient care—spiked, worrying analysts about profitability. In one particularly rough quarter, the company slashed its adjusted earnings per share guidance, sending shares down by over 22%—their worst single-day performance since 1998. When CEO Andrew Witty abruptly resigned, Stephen Hemsley was swiftly reinstalled as CEO, receiving a pay package with a $1 million base salary and $60 million in stock options set to vest over three years. The company also suspended its annual forecast, a move that sent shares tumbling another 16% and rattled investor confidence.
Despite these setbacks, UnitedHealth is still projecting more than $439 billion in revenue for 2026, with adjusted earnings per share north of $17.75 and a medical care ratio around 88.8%. CEO Hemsley, in a bid to calm nerves, told Reuters, “Momentum inside this organization is palpable.” Still, market watchers like James Harlow of Novare Capital Management remain cautious. Commenting on the Medicare proposals, Harlow warned that the changes “start to bring in worries about 2027 earnings growth.”
Investor sentiment is further complicated by the dual narratives emerging from valuation models. The bullish camp, assuming Medicare Advantage and Medicaid margin normalization and successful restructuring at Optum (UnitedHealth’s health services arm), sees a fair value of $392.24 per share, with revenue growth of 4.53% per year and earnings reaching $20 billion by 2028. The cautious narrative, on the other hand, factors in tighter CMS rates, ongoing policy probes, and regulatory pressure, pegging fair value at $284.09 per share with slower revenue growth and margin compression.
As the CMS comment window closes and the final rate announcement approaches, UnitedHealth traders are left watching policy news and sector moves for cues. The stakes are high: if the Medicare Advantage rate update remains stingy and stricter risk adjustment rules take hold, insurers may be forced to cut benefits, shrink networks, or even exit certain markets—moves that could further erode UnitedHealth’s standing.
For now, the company’s fate hangs in the balance, shaped by regulatory decisions, ongoing investigations, and the delicate trust of investors and patients alike. The coming weeks will be critical in determining whether UnitedHealth can weather this perfect storm—or if its troubles are only just beginning.